Next Science Future Growth
Future criteria checks 2/6
Next Science is forecast to grow earnings and revenue by 47.6% and 30.6% per annum respectively while EPS is expected to grow by 58.9% per annum.
Key information
47.6%
Earnings growth rate
58.9%
EPS growth rate
| Medical Equipment earnings growth | 16.0% |
| Revenue growth rate | 30.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 21 Oct 2024 |
Recent future growth updates
Recent updates
Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 36% Cheaper
Oct 22
Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 29% Bounce
Jul 26It's Down 32% But Next Science Limited (ASX:NXS) Could Be Riskier Than It Looks
Jun 08Will Next Science (ASX:NXS) Spend Its Cash Wisely?
Apr 16Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 26% Bounce
Mar 06Potential Upside For Next Science Limited (ASX:NXS) Not Without Risk
Dec 26Next Science Limited (ASX:NXS) Analysts Just Trimmed Their Revenue Forecasts By 10%
Oct 26Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 26% Cheaper
May 13The Next Science Limited (ASX:NXS) Analysts Have Been Trimming Their Sales Forecasts
Feb 03Here's Why We're Not Too Worried About Next Science's (ASX:NXS) Cash Burn Situation
Jan 25Next Science Limited (ASX:NXS) Is Expected To Breakeven In The Near Future
Mar 07Here's Why We're Watching Next Science's (ASX:NXS) Cash Burn Situation
Feb 14
Did Next Science Limited (ASX:NXS) Insiders Buy Up More Shares?
Jan 18Do Institutions Own Next Science Limited (ASX:NXS) Shares?
Dec 20What Type Of Returns Would Next Science's(ASX:NXS) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Nov 23Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 50 | -2 | N/A | N/A | 1 |
| 12/31/2025 | 39 | -9 | N/A | N/A | 1 |
| 12/31/2024 | 28 | -11 | N/A | N/A | 1 |
| 6/30/2024 | 23 | -14 | -13 | -12 | N/A |
| 3/31/2024 | 23 | -15 | -14 | -14 | N/A |
| 12/31/2023 | 22 | -16 | -16 | -15 | N/A |
| 9/30/2023 | 19 | -15 | -15 | -14 | N/A |
| 6/30/2023 | 16 | -15 | -14 | -13 | N/A |
| 3/31/2023 | 14 | -14 | -13 | -13 | N/A |
| 12/31/2022 | 12 | -13 | -12 | -12 | N/A |
| 9/30/2022 | 11 | -12 | -12 | -12 | N/A |
| 6/30/2022 | 10 | -12 | -12 | -11 | N/A |
| 3/31/2022 | 10 | -11 | -10 | -10 | N/A |
| 12/31/2021 | 9 | -9 | -9 | -8 | N/A |
| 9/30/2021 | 8 | -9 | -10 | -9 | N/A |
| 6/30/2021 | 6 | -9 | -11 | -10 | N/A |
| 3/31/2021 | 5 | -11 | -12 | -11 | N/A |
| 12/31/2020 | 3 | -12 | -13 | -12 | N/A |
| 9/30/2020 | 3 | -12 | -12 | -11 | N/A |
| 6/30/2020 | 3 | -13 | -11 | -10 | N/A |
| 3/31/2020 | 3 | -13 | -13 | -11 | N/A |
| 12/31/2019 | 4 | -14 | -14 | -12 | N/A |
| 9/30/2019 | 4 | -15 | -14 | -13 | N/A |
| 6/30/2019 | 4 | -16 | -15 | -14 | N/A |
| 3/31/2019 | 4 | -15 | -14 | -13 | N/A |
| 12/31/2018 | 3 | -14 | -13 | -12 | N/A |
| 12/31/2017 | 4 | -2 | N/A | N/A | N/A |
| 12/31/2016 | 1 | -3 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NXS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NXS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NXS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NXS's revenue (30.6% per year) is forecast to grow faster than the Australian market (5.8% per year).
High Growth Revenue: NXS's revenue (30.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NXS's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 04:54 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Next Science Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Elyse Shapiro | Bell Potter |
| Martyn Jacobs | Canaccord Genuity |
| Dr Benson | Wilsons Advisory and Stockbroking Ltd. |